Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Eli Lilly and Co DRC (LLY)

CBOE Canada
Currency in CAD
Disclaimer
34.78
+0.72(+2.11%)
Closed
LLY Scorecard
Full Analysis
Has raised its dividend for 9 consecutive years
Fair Value
Day's Range
34.0934.79
52 wk Range
20.7536.42
Bid/Ask
32.85 / 34.88
Prev. Close
34.06
Open
34.78
Day's Range
34.09-34.79
52 wk Range
20.75-36.42
Volume
36,720
Average Volume (3m)
56,716
1-Year Change
48.47%
Fair Value
Unlock
Fair Value Upside
Unlock
LLY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Eli Lilly DRC Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Employees
43000
Market
Canada

Compare LLY to Peers and Sector

Metrics to compare
LLY
Peers
Sector
Relationship
P/E Ratio
111.7x25.7x−0.6x
PEG Ratio
8.54−1.730.00
Price/Book
60.5x3.6x2.6x
Price / LTM Sales
21.1x3.5x3.2x
Upside (Analyst Target)
-0.0%48.5%
Fair Value Upside
Unlock9.2%7.8%Unlock

FAQ

What Is the Eli Lilly DRC (LLY) Stock Price Today?

The Eli Lilly DRC stock price today is 34.78.

What Stock Exchange Does Eli Lilly DRC Trade On?

Eli Lilly DRC is listed and trades on the CBOE Canada stock exchange.

What Is the Stock Symbol for Eli Lilly DRC?

The stock symbol for Eli Lilly DRC is "LLY."

What Is the Eli Lilly DRC Market Cap?

As of today, Eli Lilly DRC market cap is 1.15T.

What is Eli Lilly DRC Earnings Per Share?

The Eli Lilly DRC EPS is 8.15.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.